Dr. Bellmunt on The Cancer Genome Atlas Project in Bladder Cancer

Joaquim Bellmunt, MD, PhD
Published: Thursday, Apr 05, 2018



Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses The Cancer Genome Atlas (TCGA) project in bladder cancer.

During the 2018 Genitourinary Cancers Symposium, the final entire cohort of 412 tumors that TCGA gathered from patients with chemotherapy-naïve muscle invasive urothelial bladder cancer was reported. Bellmunt, a contributor to the study, says that the different genomic aspects of bladder cancer were analyzed such as DNA, RNA, and proteomic analysis. These results are important because these aspects have been correlated with outcome, Bellmunt explains.

According to the analysis, these findings significantly increase the ability to identify low-frequency aberrations, and provide a robust basis for functional studies aimed to better understand the biology of bladder cancer. This analysis has help establish the new profile in terms of different subtypes of RNA and DNA, which will aid in the stratification of patients for clinical trials, says Bellmunt.


Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses The Cancer Genome Atlas (TCGA) project in bladder cancer.

During the 2018 Genitourinary Cancers Symposium, the final entire cohort of 412 tumors that TCGA gathered from patients with chemotherapy-naïve muscle invasive urothelial bladder cancer was reported. Bellmunt, a contributor to the study, says that the different genomic aspects of bladder cancer were analyzed such as DNA, RNA, and proteomic analysis. These results are important because these aspects have been correlated with outcome, Bellmunt explains.

According to the analysis, these findings significantly increase the ability to identify low-frequency aberrations, and provide a robust basis for functional studies aimed to better understand the biology of bladder cancer. This analysis has help establish the new profile in terms of different subtypes of RNA and DNA, which will aid in the stratification of patients for clinical trials, says Bellmunt.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x